arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Vanda Pharmaceuticals Inc.

VNDA
$5.12 ▲ +0.46 (+9.76%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vanda Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $304.4M
Dividend Yield
Revenue Growth 3.4%
Op. Margin -97.1%
ROIC -17.9%
FCF / Share $-0.85
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.72M
↑ +3.4%
Net Income Profit after all expenses
$-48.57M
↓ -64.7%
Operating Margin Operating profit as % of sales
-97.1%
↓ -37.7% 4th
FCF / Share Free cash flow per share
$-0.85
↓ -47.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
13
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters